Weight Loss

SAN DIEGO — Combination cagrilintide and semaglutide therapy is associated with a 15.6% weight loss and 2.2% reduction in HbA1c among adults with obesity and type 2 diabetes, according to a speaker.

SAN DIEGO — Adults with obesity and type 2 diabetes achieved a 14.7% weight loss at 72 weeks with 15 mg tirzepatide, according to data from the SURMOUNT-2 trial presented at the American Diabetes Association Scientific Sessions.

SAN DIEGO — Adults with obesity and without diabetes receiving the oral GLP-1 receptor agonist orforglipron lost 8.6% to 12.6% of their body weight at 26 weeks, according to a data from a phase 2 trial.

Obesity can have a significant impact on mental health.

Results published in the Journal of Arthroplasty showed patients with class II and class III obesity do not benefit or harm from preoperative weight loss prior to total knee arthroplasty.

Adults with overweight or obesity receiving semaglutide lost 13.4% of their body weight at 1 year, according to findings from a real-world study presented at the European Congress on Obesity.

Women with polycystic ovary syndrome are more likely to attempt to lose weight multiple times and perceive themselves as having overweight compared with women without PCOS, according to a study published in Obesity.

Women with breast cancer whose BMI fell in the overweight or obese ranges achieved meaningful weight loss via a telephone-based intervention, according to phase 3 study results.

Adolescents with obesity whose inability to control their hunger is a barrier to weight loss have a more negative perception about their body than adolescents who say inability to control hunger is not a barrier, according to a speaker.

Adults with overweight or obesity, but not type 2 diabetes, lost 14.9% of their body weight after 46 weeks of receiving BI 456906, a novel glucagon/GLP-1 receptor agonist, during a phase 2 clinical trial, according to a press release.